Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Swartz

Showing results (261-270 of 265) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 265 results.
Biochemistry|November 17, 2011
Reconstitution of KCNE1 into lipid bilayers: comparing the structural, dynamic, and activity differences in micelle and vesicle environmentsAaron T Coey, Indra D Sahu, Thusitha S Gunasekera, et al.
The Journal of Clinical Psychiatry|September 7, 2010
Treatment outcomes of patients with tardive dyskinesia and chronic schizophreniaStanley N Caroff, Vicki G Davis, Del D Miller, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approachR A Smith, J Barbosa, C L Blum, et al.
Archives of General Psychiatry|June 6, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialRichard S E Keefe, Robert M Bilder, Sonia M Davis, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2001
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureasA M Redman, J S Johnson, R Dally, et al.
Pageof 27

Showing results (261-270 of 265) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 265 results.
Biochemistry|November 17, 2011
Reconstitution of KCNE1 into lipid bilayers: comparing the structural, dynamic, and activity differences in micelle and vesicle environmentsAaron T Coey, Indra D Sahu, Thusitha S Gunasekera, et al.
The Journal of Clinical Psychiatry|September 7, 2010
Treatment outcomes of patients with tardive dyskinesia and chronic schizophreniaStanley N Caroff, Vicki G Davis, Del D Miller, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approachR A Smith, J Barbosa, C L Blum, et al.
Archives of General Psychiatry|June 6, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialRichard S E Keefe, Robert M Bilder, Sonia M Davis, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2001
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureasA M Redman, J S Johnson, R Dally, et al.
Pageof 27